Eye Care — Procurement & Cost Guide

Key Technical Parameters #

Eye care is one of the highest-margin, highest-complexity subcategories in facial skincare — and it’s also one of the easiest to over-spend on without realizing it. Brand owners coming to us for eye cream, eye serum, or eye patch development almost always anchor on unit cost first. That’s the wrong place to start. The real cost variables are substrate selection, active concentration thresholds, fill weight, and secondary packaging compatibility, and getting any one of those wrong can push a $4.20 landed cost to $6.80 before you’ve changed a single formula. This guide is written for buyers and product developers who are past the “what ingredients work” stage and are now asking: how do I structure this project so it doesn’t blow the margin model?

What Actually Drives Unit Cost in Eye Care — and What Doesn’t #

The three cost drivers most brands underestimate are fill weight, active load, and substrate choice for patches. Everything else — fragrance level, packaging finish, color cosmetic tint — matters, but these three account for roughly 70% of the formulation cost delta we see across comparable projects.

Fill weight is deceptively simple. Eye creams typically run 15ml or 15g. Sounds obvious. But we regularly see briefs specifying 20g because the brand wants perceived value parity with a face cream. At our production scale, the difference between a 15g and 20g eye cream in a glass jar isn’t just the extra 5g of formula — it’s a different jar spec, a different secondary box dimension, and sometimes a different carton count per pallet. Across a 5,000-unit MOQ, that cascades into a meaningful cost delta before the formula cost even enters the calculation.

Active load is where the real decisions happen. Peptide complexes, encapsulated retinol, and stabilized vitamin C derivatives each carry different input costs, and the cost curve isn’t linear. A brief requesting 3% Matrixyl 3000 costs roughly 2.2x the raw material input of a 1% concentration — but the clinical differentiation between 1% and 3% in a 12-week consumer study is often within noise. We try to have this conversation early. Sometimes brands are anchored on a competitor’s marketing claim without knowing what concentration that competitor is actually running.

Substrate for patches is the starkest example. Bio-cellulose patches run approximately 3–4x the substrate cost of hydrogel at equivalent weight. The delivery kinetics are genuinely different — bio-cellulose has demonstrated higher active retention across 30-minute wear in internal testing — but for a brand launching at a $28 retail price point, that substrate cost premium often breaks the margin model entirely. Hydrogel at 60–65% water content, properly optimized, performs well for the majority of brightening and depuffing actives.

One thing worth flagging: fragrance in eye area products adds cost but rarely adds performance. At our periorbital formulation standards (fragrance at 0.1% maximum or zero), the cost difference is marginal. But we’ve had clients request “a light floral note” in an eye cream, and that decision triggers ophthalmologist-test requirements in some EU markets — which adds 6–8 weeks to the timeline and a certification cost that wasn’t in the original budget.

Cost Structure Benchmarks: Where Your Budget Goes #

The table below reflects our actual costing structure across three representative eye care formats, based on 2024 production data at our facility. These are ex-works costs at 5,000-unit MOQ. Landed cost to your market will differ based on freight, duties, and compliance testing.

A few things to read into this table carefully. The serum range looks lower than eye cream — it often is on formula cost, but dropper bottle assembly and leak testing add back into the total. Eye patches carry a deceptively high MOQ because the filling and sealing equipment setup cost gets amortized across units; below 10,000 pairs, the setup charge dominates.

The variable most brands get wrong is comparing unit cost across formats without normalizing for what the retail price architecture requires. A $0.95/pair hydrogel patch sold at $24 for 20 pairs is a very different margin story than the same patch positioned in a prestige set at $48. The procurement decision needs to be made with the retail positioning already confirmed, not the other way around.

TCO vs Unit Price: The Calculation Most Briefs Skip #

Total cost of ownership in eye care procurement involves at least five components that rarely appear in the initial quote request: formula development fee, stability testing, regulatory compliance documentation, safety assessment, and any ophthalmologist or dermatologist testing required for claims.

At our lab, a standard eye care development project — new formula, not an adaptation — carries a development fee of $800–$1,500 depending on complexity. That fee is typically waived or credited against first production order above a threshold (usually $15,000 ex-works). For brands launching a three-SKU eye care line simultaneously, the development cost is often structured as a single project, which changes the per-SKU economics significantly.

Stability testing for eye area products follows ICH Stability Guidelines for cosmetics: accelerated conditions at 40°C/75% RH for 6 months, with real-time 25°C data initiated concurrently. For ophthalmic-adjacent claims, some markets require additional HET-CAM or equivalent ocular tolerance testing. That adds cost and time — typically 4–6 weeks and $400–$800 per test depending on the testing laboratory. Brands entering the EU market should also be aware that the EU Cosmetics Regulation 1223/2009 requires a full Cosmetic Product Safety Report (CPSR) before market placement, and a CPSR for an eye care product with novel actives can cost €800–€2,000 from a qualified EU safety assessor.

For the US market, FDA Cosmetics Guidelines don’t require pre-market approval, but any “reduces dark circles” or “lifts and firms” claim language needs to stay on the cosmetic side of the drug claim boundary. We flag this in every kickoff call because brand teams sometimes arrive with copy already written by their marketing agency — copy that, in at least three cases last year, would have triggered OTC drug classification under FDA’s framework.

The NMPA registration pathway for eye care products sold in China adds another cost layer entirely. Under NMPA Cosmetic Regulation, eye area products are classified as ordinary cosmetics, but if the formula contains certain actives (notably, anything classified as a new cosmetic ingredient in China post-2021), registration timelines can extend to 12–18 months. Budget accordingly if China is in your distribution plan.

A 2022 open-label clinical study (n=44, 8 weeks, twice-daily application) on a caffeine-peptide eye contour serum demonstrated a 27% reduction in periorbital puffiness score at week 8 as measured by optical profilometry. The study also showed a 19% improvement in dark circle colorimetry (L* value increase) at the same endpoint. We reference this internally when brands ask whether an 8-week study is sufficient for efficacy substantiation — for depuffing and vascular dark circles, it generally is. For wrinkle depth endpoints, 12 weeks is more defensible.

Supplier Qualification Criteria: What to Actually Evaluate #

Our internal qualification process — we run this under what we call the SQ-12 supplier assessment protocol — covers six categories: GMP certification status, formulation capability documentation, stability testing infrastructure, regulatory documentation support, minimum batch size relative to your MOQ, and communication responsiveness on technical queries.

The GMP piece sounds basic but deserves scrutiny. ISO 22716 certification is the baseline ISO Standards for cosmetic GMP, but certification scope varies. Some facilities are certified for fill-and-finish only; their formulation development happens in a separate, uncertified space. Ask for the certification scope document, not just the certificate. This distinction matters when your CPSR assessor or a retail buyer’s audit team asks whether the formula was developed under GMP conditions.

Stability testing infrastructure is the qualification criterion that separates contract manufacturers worth working with from those that aren’t. Any supplier worth briefing should have in-house stability chambers running ICH-compliant conditions, a documented protocol with defined testing intervals (0, 4, 8, 12, 26 weeks at minimum), and the ability to provide batch-specific data rather than “representative stability data” from a similar formula. We’re not fully convinced that “similar formula” stability data is ever adequate for a new launch. It’s a shortcut that creates liability later.

Documentation support for EU and US markets is increasingly a differentiator. Compiling the PIF (Product Information File) for EU, including INCI list, manufacturing process summary, product specifications, and cosmetic product safety assessment, requires coordination across formulation, QC, and regulatory teams. Suppliers who treat this as an afterthought will slow your market entry by months. Ask prospective suppliers for a sample redacted PIF from a previous project — their willingness to provide it and the quality of what they share tells you a lot.

One area where opinions differ across our industry: how frequently to requalify suppliers on key raw materials. Some OEM partners requalify annually regardless. Others only requalify after formula changes or supplier-side ingredient source changes. Our practice is annual requalification for actives above 0.5% concentration and immediate requalification whenever a raw material supplier notifies us of a process or source change. For stable base ingredients, we run a biannual check. Neither approach is universally right — it depends on your risk tolerance and your retail customers’ audit expectations.

Stocking Strategy and MOQ Negotiation for Eye Care #

Eye care SKUs present a specific stocking challenge: the periorbital category has strong seasonality in some markets (eye patches spike in Q4 gifting and Q1 “post-holiday recovery” positioning) but relatively flat replenishment elsewhere. Getting the stocking strategy wrong in year one usually means either a stockout at launch or excess inventory sitting at 25°C for 18 months while you wait for sell-through.

For brands launching their first eye care SKU, we generally recommend starting at the floor MOQ (3,000 units for creams and serums; 10,000 pairs for patches) and building safety stock through a second run rather than over-ordering at launch. The cost-per-unit argument for running 10,000 units instead of 3,000 on a cream is real — typically a 12–18% unit cost reduction — but that saving evaporates if you’re carrying inventory for 14 months.

The negotiation variable most buyers overlook is shared tooling and component costs. If your eye cream and face cream are both running in 30g glass jars from the same mold, the secondary packaging tooling cost disappears from the eye care project entirely. We actively look for these overlaps when brands brief multiple SKUs simultaneously, and it’s one of the stronger arguments for doing a full line brief rather than launching sequentially.

For ongoing supply agreements, we recommend specifying a rolling 90-day forecast commitment rather than a fixed annual PO. This gives us enough visibility to hold raw material inventory for your actives — particularly for peptides with 8–12 week lead times — without requiring you to commit capital before sell-through data exists. Some suppliers won’t offer this flexibility below a certain annual volume threshold, which is a fair commercial position. Know that threshold before you negotiate.

Prevention — What to Specify Upfront #

Put the target market and claims list in the brief before the formula brief. The compliance burden for an eye cream sold in the EU with “clinically proven to reduce wrinkles” copy is fundamentally different from the same formula sold in the US with “visibly reduces fine lines.” Getting this backwards adds 8–12 weeks and cost that wasn’t in the model.

Specify packaging material and supplier preference before formulation begins. Formula-packaging compatibility testing takes 4–8 weeks and is non-negotiable; starting it late is the most common cause of timeline overruns in eye care projects.

Request three documents from any prospective supplier at qualification stage: a sample INCI specification sheet, a redacted stability study from a recent eye care project, and their ISO 22716 certificate with scope annotation. If any of these are unavailable or incomplete, that’s diagnostic information.

Formulation Notes for Brand Partners #

When you brief us on an eye care project, the first question isn’t “what actives do you want?” It’s: what market, what retail channel, and what’s the on-pack claim story? Those three answers determine the compliance pathway before we write a single formula.

The brief mistake we see most often is arriving with an active wishlist assembled from competitor benchmarking — 3 peptides, encapsulated retinol, vitamin C derivative, caffeine — without a unit cost ceiling. When we cost that out at a reasonable concentration for each active, we’re usually 40–60% over the brand’s implied price architecture. The reframe we use: rank your actives by the claim they support, confirm which claim is primary, and build the formula around that claim first. Secondary actives come in where budget allows.

On timeline: lab samples in 2–3 weeks for adaptations, 4–5 weeks for new development. Accelerated stability runs 4–8 weeks at 40°C/75% RH; 24-month real-time stability is initiated concurrently from day one of production. Regulatory documentation — CPSR for EU, NMPA filing package for China — runs in parallel but requires your registered responsible person details before we can finalize. Don’t wait for stability to start the regulatory track.

For eye-care projects specifically, we also flag packaging compatibility testing as a parallel workstream from week one, not an afterthought. It’s saved multiple projects from a 6-week delay.

Frequently Asked Questions #

We’ve been quoted $1.80 per unit by another supplier. Can you match it?
A: At $1.80 ex-works for an eye cream, the formula is almost certainly a simple emulsion base with minimal active load, in a plastic jar or basic tube. That’s a legitimate product if it matches your positioning — but compare it against the spec sheet, not just the price. We’d want to see the INCI list and stability data before saying anything about matchability.

Do we need ophthalmologist testing to sell in the EU?
A: Not always, but it depends on your claims. Under EU Cosmetics Regulation 1223/2009, ophthalmologist testing isn’t a blanket requirement — it’s typically required when you’re making proximity-to-eye claims or when your safety assessor flags the formula as requiring additional ocular tolerance evidence. Budget for it as a possibility, especially if your formula contains retinoids or high-load exfoliants in the eye area.

What’s the most common stability failure you see in eye care products?
A: Phase separation in eye creams at the 8-week accelerated mark, usually traced back to emulsifier concentration being too lean — below 2.5% total emulsifier in formulas with high water activity. We also see vitamin C derivatives (particularly ascorbyl glucoside) discoloring in clear serum formats when packaging isn’t UV-blocking. Both are fixable at formulation stage; catching them after first production is expensive.

What’s the realistic MOQ if we’re launching just one eye patch SKU?
A: Floor MOQ for hydrogel eye patches is 10,000 pairs, and that number is driven by filling equipment setup amortization, not minimum formula batch size. The formula batch could technically be smaller. If you’re not ready for 10,000 pairs, a co-development with a second SKU — say, a brightening patch and a depuffing patch sharing the same hydrogel base — can make the combined MOQ work for both variants simultaneously.

Should we be worried about our peptide supplier changing their manufacturing process?
A: Yes, and this is worth building into your supply agreement explicitly. Peptide synthesis sources can shift — different fermentation batches, different purification grades — and the CoA might look identical while the actual performance in your formula drifts. Our peptide-growth-factor intake protocol includes a bioactivity check on incoming lots, not just purity. Ask your supplier whether they have a change notification obligation in their raw material supply agreements. Many don’t, by default.

---

Have a product concept in mind? Contact our formulation team to request a complimentary brief review.